Cell therapy

#Autoimmune disease #CAR-T #Cell therapy #FDA #Lupus #Synthekine

CAR-T and orthogonal IL-2 therapy for lupus fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted fast track designation to SYNCAR-001 + STK-009. The treatment is indicated for patients with severe, refractory systemic lupus erythematosus (SLE), without the use of lymphodepletion. The fast-track designation follows investigational new drug (IND) clearance for a Phase I study evaluating SYNCAR-001… Read More

#News #Regulatory

Liver cancer
#Cell therapy #FDA #Grit Biotechnology #Oncology #Solid tumours

FDA clears genetically engineered TIL therapy for solid tumour trials

Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201. The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for… Read More

#Cancer Research #News #Regulatory

Gene therapy concept
#Cell and gene therapy #Cell manufacturing #Cell therapy #Gene therapy

Looking ahead for cell and gene therapy

DDW’s Megan Thomas discusses the future of the cell and gene therapy (CGT) sector with industry experts, who predict what to expect in 2024 and beyond. Emphasis on manufacturing  Experts were unanimous in their view of how far the cell & gene therapy (CGT) sector has come and the milestones… Read More

#Exclusive Content

CAR-T therapy
#CAR-T #Cell therapy #China #Legend Biotech #Myeloma #Oncology

Legend Biotech secures China cilta-cel approval for multiple myeloma

Legend Biotech (a subsidiary of GenScript Biotech) has received approval from the China National Medical Products Administration (NMPA) for cell therapy product, ciltacabtagene autoleucel (cilta-cel). The treatment is approved for use in adults with relapsed or refractory multiple myeloma (MM) who have undergone at least three prior lines of therapy,… Read More

#News #Regulatory

CAR-T cell therapy
#CAR-T #Cell and gene therapy #Cell therapy #Lymphoma #Oncology

The curative potential of CAR-T cell therapy

Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector.  MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you… Read More

#Cancer Research #Exclusive Content

T cell attacking cancer cell
#Cell therapy #Citius Pharmaceuticals #FDA #Lymphoma #Mergers and acquisitions #Oncology

Citius Oncology launches following FDA approval of Lymphir

The US Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl) for the second-line treatment of r/r cutaneous T-cell lymphoma (CTCL), making it Citius Pharma’s first product approved in the US. Lymphir is a novel immunotherapy and the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on… Read More

#Business & Investment #News #Regulatory

#Cell and gene therapy #Cell therapy #Gene therapy

Reflecting on the past and present of CGT development

DDW Multimedia Editor Megan Thomas speaks to industry experts to reflect on where the industry and has come over the last year, gain an understanding of what to expect from the 2024 cell & gene therapy (CGT) sector, and where future opportunities may lie. Workforce development and training Bruce Levine,… Read More

#Exclusive Content

CAR-T therapy
#Biosyngen #CAR-T #Cell therapy #FDA #Head and neck cancer #Oncology #Solid tumours

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma. The Center for… Read More

#News #Regulatory

#Cell therapy #Funding #Japan #Oncology #Shinobi Therapeutics

Shinobi Therapeutics secures $59M grant for iPS-T cell therapy

Shinobi Therapeutics has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The funds will support the development of Shinobi's lead iPS-T cell programme targeting GPC3+ tumours. Shinobi also announced an extension of its Series A round, bringing the… Read More

#Business & Investment #News

Soft tissue sarcoma
#Adaptimmune Therapeutics #Cell therapy #FDA #Oncology #Solid tumours

First engineered cell therapy for a solid tumour gets US approval

Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel) has become the first engineered cell therapy for a solid tumour cancer approved in the US. It is also the first new therapy option in more than a decade for synovial sarcoma, which is a rare, soft tissue cancer that most commonly impacts young adults. Read More

#News #Regulatory #Trending News

Knee x-ray
#allogeneic cell therapies #Australia #Cell therapy #Magellan Stem Cells #Osteoarthritis #Stem cells

Donor stem cell therapy delays progression of osteoarthritis

New research by Australian biotechnology company Magellan Stem Cells has demonstrated potential therapeutic benefits of a stem cell therapy for osteoarthritis. The Phase I/II clinical trial assessed the safety and efficacy of MAG200, Magellan Stem Cells’ off-the-shelf allogeneic (donor) stem cell therapy for osteoarthritis of the… Read More

#News

Human brain
#Cell and gene therapy #Cell therapy #Gene therapy #Neurodegenerative disorders #Neuroscience

Five cell and gene therapy advances in neurodegeneration

Neurodegenerative diseases have recently increased at an alarming rate due to the ageing global population. There are a number of cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Diana Spencer provides an overview. A neurorestorative treatment Asklepios BioPharmaceutical’s (AskBio’s) AB-1005 is an adeno-associated virus… Read More

#Exclusive Content

#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

New eBook: Creating opportunities from advanced therapies

Cell and gene therapies (CGTs) are the fastest growing area of therapeutics, with many preclinical and clinical programmes currently underway. While cancer is key target for CGTs, these advanced therapies are also under investigation to treat conditions as varied as asthma, multiple sclerosis, ophthalmological conditions like… Read More

#News

DDW Cell and gene therapy eBook
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Cell & gene therapy: Creating opportunities from advanced therapies

This eBook explores the current challenges and opportunities in the cell and gene therapy (CGT) space, and the factors likely to influence this area of therapeutics in the future. Download this exclusive eBook to learn more about: How innovative approaches are taking CGTs from bench to bedside The importance of… Read More

#DDW eBooks #Intelligence

#Advanced Therapies #Advanced Therapy Medicinal Products (ATMPs) #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Guide #Market reporting

Podcast: The global innovation and the opportunity in CGTs

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers five articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The promise and growth of cell and gene therapies… Read More

#News